2 Reasons Why Novavax Investors Should Be Cautious

With its shares down more than 48% this year, I can't blame Novavax (NASDAQ: NVAX) shareholders for getting skittish. The vaccine developer's fortunes have taken a battering amid quite a few delays in getting its first product, a coronavirus shot, approved. And now, seemingly with one foot over the finish line, there are a couple of fresh issues with the company that should give investors pause.

Neither of the obstacles I'll discuss today are insurmountable, but they both pose substantial risk to Novavax's stock, so let's take a look.

Image source: Getty Images.

Source Fool.com